Public Video Library

Discussion of zanubrutinib (BRUKINSA®) for Adult Patients with CLL/SLL
October 31, 2025

Presenter:
-Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC | Minnesota Oncology

Key Learnings:
-Describe the mechanism of action and therapeutic role of BTK inhibitors in oncology.
-Summarize recent NCCN guideline updates relevant to BTK inhibitor use.
-Analyze key findings from the ALPINE and SEQUOIA clinical trials to inform clinical decision-making.
-Evaluate patient case studies to identify optimal treatment strategies and access pathways.
-Explain the pricing, distribution, and patient support services associated with BTK inhibitor therapies.

Disclaimer:
-The information presented in this webinar is accurate as of the time of recording. However, clinical guidelines, prescribing information, and best practices may evolve over time. We encourage all members to refer to the most current prescribing information, clinical guidelines, and regulatory updates for the latest and most accurate details regarding medications and treatment recommendations.
-Please note that this webinar recording and slides are intended for a U.S. audience.

#Zanubrutinib
#Brukinsa
#BeOne
#Tablet
#ChronicLymphocyticLeukemia
#SmallLymphocyticLeukemia
#CLL
#SLL